Exagen Inc. (XGN) stock
Close on Nov 12, 2026Market cap $106.83MP/E –Yield –
Exagen Inc. grew revenue 13.7% to $72.30M over the twelve months to Sep 30, 2026. Free cash flow was -$13.03M. At the latest close the market valued the company at $106.83M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $106.83M
- P/E ratio
- –
- Price to sales
- 1.48
- Price to book
- 7.76
- Dividend yield
- –
- Free cash flow yield
- -12.19%
Fundamentals
- Revenue
- $72.30M
- Net income
- -$18.17M
- EPS, diluted
- -$0.75
- Free cash flow
- -$13.03M
- Book value per share
- $0.55
- Diluted shares
- 25M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $5.04
- Open
- $5.02
- Day's range
- $4.39 – $5.10
- Volume
- 1,368,577
- Average volume (20 days)
- 581,895
- Beta (5 years)
- 1.20
- 52-week range
- $2.59 – $9.73
- RSI (14 days)
- 29.9
- Volatility (1 year)
- 94.4%
- Relative volume
- 3.61×
- WACC
- 11.0%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | XGN | S&P 500 | Difference | XGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.5% | -2.7% | −43.8 pts | ||
| 3 months | -33.1% | -1.7% | −31.3 pts | ||
| Year to date | -27.5% | +11.9% | −39.4 pts | ||
| 1 year | -54.0% | +12.0% | −66.0 pts | ||
| 3 years | +204.1% | +78.2% | +126.0 pts | +44.9% | +21.2% |
| 5 years | -65.7% | +73.2% | −139.0 pts | -19.3% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Exagen filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Exagen
Services-Medical Laboratories
Exagen is a medical technology company that develops and commercializes diagnostic, prognostic, and monitoring testing products focused on complex rheumatic and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. The company provides a suite of ten commercialized tests under the AVISE brand name, featuring its connective tissue disease panel alongside specialized assays for disease prognosis, vasculitis, and therapeutic drug monitoring. Its testing services support rheumatologists, primary care physicians, other medical specialists, hospitals, and healthcare systems.
Company profile, executives and historyExagen stock: common questions
What is Exagen's stock price?
XGN closed at $4.41 on Nov 12, 2026, down 12.41% on the day. Over the past 52 weeks it traded between $2.59 and $9.73.
What is Exagen's market cap?
Exagen was worth $106.83M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is XGN's P/E ratio?
Exagen lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.75), so it has no meaningful P/E ratio.
How much revenue does Exagen make?
Exagen reported revenue of $72.30M for the twelve months to Sep 30, 2026, up 13.7% from a year earlier.
Does Exagen pay a dividend?
No. Exagen has not paid a cash dividend over the last twelve months.
When does Exagen report earnings next?
Exagen is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has XGN stock performed over the past year?
Including dividends, XGN returned -54.0% over the past year, against +12.0% for the S&P 500.
How many XGN shares are sold short?
1M shares were sold short at the latest FINRA report, 4.24% of the float, or 2.0 days of average trading volume.
Who are Exagen's competitors?
Companies most similar to Exagen by business, industry and size include BDSX, PSNL, MDXH, GRAL, CSTL.
See a number that looks wrong?